Form 4: Day One Biopharma CCO Granted Equity Awards

Day One Biopharmaceuticals' Chief Commercial Officer, Lauren Merendino, was granted 110,000 stock options and 74,000 restricted stock units.

Summary

• Lauren Merendino, Chief Commercial Officer of Day One Biopharmaceuticals, Inc. (DAWN), reported the acquisition of derivative securities.
• The transaction involved the grant of 110,000 stock options with an exercise price of $11.16 per share.
• The stock options vest as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to continued service.
• The stock options have an expiration date of January 29, 2036.
• Additionally, 74,000 Restricted Stock Units (RSUs) were granted.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
• The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15, and November 15, subject to continued service.
• RSUs do not expire but either vest or are canceled prior to the vesting date.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices aimed at retaining key talent and aligning management incentives with shareholder interests. It does not indicate any immediate operational or financial changes.

Positives

• The equity grants align the Chief Commercial Officer's interests with those of shareholders, incentivizing long-term performance.
• The grants serve as a retention mechanism for key executive talent within the company.

Risks

• The value of the stock options and RSUs is subject to the future market price of Day One Biopharmaceuticals' common stock, which can fluctuate.
• Vesting of the awards is contingent upon the reporting person's continued provision of service to the Issuer, meaning unvested awards could be forfeited upon departure.

Future Outlook

The equity grants are designed to incentivize the Chief Commercial Officer's long-term commitment and performance, aligning her financial interests with the company's future success and shareholder value creation.

Management Comments

• The grants are part of the company's executive compensation strategy to attract, retain, and motivate key personnel.

Industry Context

StockSavvy.ai notes that equity-based compensation, such as stock options and restricted stock units, is a standard practice across the biotechnology and pharmaceutical industries. This approach is widely used to align the interests of executives with those of shareholders, particularly in growth-oriented companies like Day One Biopharmaceuticals, where long-term value creation is paramount.

Comparison to Industry Standards

• The use of stock options and restricted stock units for executive compensation is consistent with common practices observed in comparable biotech companies, such as Mirati Therapeutics (MRTX) or Zymeworks (ZYME), which frequently utilize similar equity incentives to attract and retain top talent.
• The vesting schedules, with monthly and quarterly increments over several years, are typical for executive equity awards, aiming to foster long-term commitment rather than short-term gains.

Related Party Transactions

• The equity grants to the Chief Commercial Officer represent a form of related party transaction, as they involve compensation provided to an executive of the company.

Stakeholder Impact

• Shareholders: Potential benefit from increased alignment of executive interests with long-term company performance and value creation.
• Employees (specifically the CCO): Direct financial incentive and retention mechanism through equity ownership.

Next Steps

• Continued provision of service by the Chief Commercial Officer to ensure vesting of the granted equity awards.

Key Dates

Recommendation

This Form 4 filing reports routine executive compensation in the form of equity grants. It does not contain new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. The grants are a standard practice for executive retention and alignment.

Keywords

Day One Biopharmaceuticals, DAWN, Lauren Merendino, Stock Options, Restricted Stock Units, Equity Compensation, SEC Form 4, Insider Transaction, Executive Compensation